Company intelligence / Profile preview

Hangzhou Biosun Pharmaceutical Co., Ltd.

Hangzhou, Zhejiang Province, Chinaen.biosunpharmed.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Their investigative JAK2 inhibitor OB756 (bonretinib) demonstrated favorable tolerability and meaningful clinical activity in Chinese patients with myelofibrosis who had no prior exposure to JAK inhibition. In a Phase 1/2 study, 54.5% of evaluable patients achieved a spleen volume reduction of at least 35% at the end of cycle 6, with no dose-limiting toxicities reported[9].

Therapeutic areas: Hematology
Modalities: Small moleculesJAK inhibitors
Industry: Biotech

Drug pipeline

1 asset

OB756

NDA

Indications: Not specified

Partnerships

The First Affiliated Hospital of Zhejiang University School of Medicine[9]

Beyond the preview

Go deeper on Hangzhou Biosun Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Biosun Pharmaceutical Co., Ltd..

Explore the full profile